Quick Answer
Emmaus Life Sciences, Inc. reported Research And Development Expense of $313.0 thousand for the year ending 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -52.4% in Research And Development Expense from 2024 to 2025.
- This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $466.0 thousand | Q1 2019: $513.0 thousand | Q2 2019: $540.0 thousand | Q3 2019: $725.0 thousand | Q1 2020: $617.0 thousand | Q2 2020: $589.0 thousand | Q3 2020: $629.0 thousand | Q1 2021: $1.81 million | Q2 2021: $753.0 thousand | Q3 2021: $470.0 thousand | Q1 2022: $466.0 thousand | Q2 2022: $298.0 thousand | Q3 2022: $432.0 thousand | Q1 2023: $289.0 thousand | Q2 2023: $320.0 thousand | Q3 2023: $414.0 thousand | Q1 2024: $183.0 thousand | Q2 2024: $191.0 thousand | Q3 2024: $146.0 thousand | Q1 2025: $176.0 thousand | Q2 2025: $56.0 thousand | Q3 2025: $50.0 thousand.
- Over the full 8 years of available data (2018 to 2025), Emmaus Life Sciences, Inc.'s Research And Development Expense has declined by 81.8%.
- Historical annual values: Fiscal year 2025: $313.0 thousand | Fiscal year 2024: $657.0 thousand | Fiscal year 2023: $1.19 million | Fiscal year 2022: $1.73 million | Fiscal year 2021: $4.11 million | Fiscal year 2020: $2.41 million | Fiscal year 2019: $2.18 million | Fiscal year 2018: $1.72 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: